Immunization

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

Cases of meningococcal disease currently exceed prepandemic levels.

Dozens of presentations at IDWeek 2024 focused on available immunizations, such as those for COVID-19, respiratory syncytial virus, and flu.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.

The pilot Will Evaluate Measure Concepts and Data Exchange in Value-Based Arrangements.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.

Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

The National Foundation for Infectious Diseases released a survey regarding the feelings of US adults toward influenza, COVID-19, RSV, and pneumococcal disease.

Researchers aimed to address how community pharmacies target vulnerable groups regarding the promotion of vaccinations.

Catch up on important immunization news from the month of September.

The vaccine will be made available via third-party online pharmacies.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.

The MVA-BN vaccine is manufactured by Bavarian Nordic and has shown strong efficacy against mpox infection in real-world studies.

Industry experts and physicians conducted a state-by-state breakdown of vaccination statistics for children and teenagers as well as adults and elderly individuals.

Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.

The vaccine, VAX-31, targets 20 serotypes in common with PCV20, as well as 11 additional serotypes.

The protein-based vaccine includes a monovalent component corresponding to the Omicron variant JN.1 strain.

Catch up on important immunization news from the month of August.

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around the importance of COVID-19 vaccines.

Emergent BioSolutions has announced that it will donate 50,000 doses of ACAM2000 for potential deployment across affected areas in Central Africa.